Palisade Bio, Inc.

Palisade Bio, Inc. is a clinical-stage biopharmaceutical firm dedicated to identifying, advancing, and bringing to market orally administered treatments for significant conditions stemming from a compromised gastrointestinal mucosal barrier. The company's primary therapeutic candidate, LB1148, is an oral liquid formulation designed to inhibit digestive enzymes. Its goal is to safeguard gut integrity when the intestine experiences stress due to factors such as diminished blood supply, infections, or surgical procedures. Established in 2005, the company maintains its headquarters in Carlsbad, California.